(Q34030168)

30 July 2017

1 reference

title

Psychopharmacology and mental retardation: a 10 year review (1990-1999). (English)

1 reference

30 July 2017

Matson JL

1

1 reference

30 July 2017

Bamburg JW

2

1 reference

30 July 2017

Mayville EA

3

1 reference

30 July 2017

Pinkston J

4

1 reference

30 July 2017

Bielecki J

5

1 reference

30 July 2017

Kuhn D

6

1 reference

30 July 2017

Smalls Y

7

1 reference

30 July 2017

Logan JR

8

1 reference

30 July 2017

publication date

1 July 2000

1 reference

Research in Developmental Disabilities

30 July 2017

published in

1 reference

30 July 2017

volume

21

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

263-296

1 reference

Phenobarbital-induced disinhibition in the developmentally disabled: case report

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Pharmacologic control of aberrant behavior in the mentally retarded: toward a more rational approach

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Naltrexone and fluoxetine in Prader-Willi syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Case study: paradoxical response to naltrexone treatment of self-injurious behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Opiate antagonists for recurrent self-injurious behavior in three mentally retarded adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Naltrexone in autistic children: behavioral symptoms and attentional learning

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Risperidone for aggression and self-injurious behavior in adults with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Cessation of long-term naltrexone therapy and self-injury: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Paroxetine treatment of aggression and self-injury in persons with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Catatonic syndrome following recovery from neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Assessing independent and interactive effects of behavioral and pharmacologic interventions for a client with dual diagnoses.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Using analog baselines to assess the effects of naltrexone on self-injurious behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Neuroleptic-induced dementia documented in four adults with mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Brief report: haloperidol treatment of trichotillomania in a boy with autism and mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Fluoxetine in autism with depression

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Differential response of seven subjects with autistic disorder to clomipramine and desipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

The effect of clozapine on self-injurious behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Case study: risperidone treatment of children and adolescents with developmental disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Risperidone and explosive aggressive autism

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Adverse effects of clomipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Verapamil and valproic acid treatment of prolonged mania.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Brief report: a case of schizophrenia in a population with Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

An open trial of risperidone in young autistic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Rett syndrome: controlled study of an oral opiate antagonist, naltrexone.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Risperidone in the treatment of pervasive developmental disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Clinical effects of buspirone on intractable self-injury in adults with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Fluoxetine treatment of severe self-injury in young adults with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Effects of thioridazine and visual screening on stereotypy and social behavior in individuals with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

The management of chronic behavior disorders in mentally retarded adults with lithium carbonate.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Use of pimozide in the Pisa syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Effect of naltrexone upon self-injurious behavior, learning and activity: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

A case report of naltrexone treatment of self-injury and social withdrawal in autism

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

Epidemiology and prevalence of psychopathology in people with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-4222%2800%2900042-1

7 January 2021

10.1016/S0891-4222(00)00042-1

Identifiers

DOI

1 reference

30 July 2017

1 reference